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Gefitinib (‘Iressa’, ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has
demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels
could predict for response to gefitinib in patients with advanced non-small-cell lung cancer (NSCLC), who received gefitinib
(250mgday
 1) as part of a worldwide compassionate-use programme. Tissue samples were analysed by immunohistochemistry to
assess membrane EGFR immunoreactivity. Of 147 patients enrolled in our institution, 50 patients were evaluable for assessment of
both clinical response and EGFR expression. The objective tumour response rate was 10% and disease control was achieved in 50%
of patients. Although high EGFR expression was more common in squamous-cell carcinomas than adenocarcinomas, all objective
responses were observed in patients with adenocarcinoma. Response and disease control with gefitinib were not associated with high
EGFR expression. Overall, median survival was 4 months, and the 1-year survival rate was 18%. Strong EGFR staining correlated with
shorter survival time for all patients. Gefitinib demonstrated promising clinical activity in this group of patients with NSCLC. These
results have also shown that EGFR expression is not a significant predictive factor for response to gefitinib.
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The epidermal growth factor receptor (EGFR) is an important
target for anticancer therapy. It is expressed or highly expressed in
a variety of solid tumours, such as breast, head and neck, prostate,
and non-small-cell lung cancer (NSCLC) (Salomon et al, 1995).
Some studies have indicated that high baseline EGFR expression is
associated with poor prognosis in patients with NSCLC (Volm et al,
1998; Ohsaki et al, 2000). Activation of the EGFR initiates a
network of downstream pathways that are implicated in tumori-
genic processes such as cell survival, proliferation, metastasis and
decreased apoptosis (Wells, 2000). The design of several novel
biological agents has centred on specifically inhibiting this key
factor in tumour biology and encouraging clinical results have
been observed.
In parallel with the promising development of anti-EGFR
approaches, there has been considerable interest in examining
the EGFR as a predictive factor for response to these agents.
Identification of predictive factors for clinical outcome is important
for all treatment strategies for NSCLC, to aid the management of
this disease. Disease characteristics such as performance status
(PS), histological subtype and weight loss have been investigated as
possible prognostic parameters (Paesmans et al, 1995; Takigawa
et al, 1996). Recent attention has also focused on a number of
biological markers such as the EGFR, the tumour suppressor p53,
the proliferation marker Ki67 and the apoptosis regulator Bcl-2
(Nicholson et al, 2001; Brundage et al, 2002; Martin et al, 2003). It
is not yet clear whether the EGFR is a useful predictive factor for
response to EGFR-targeted agents, and the current evidence does
not support EGFR screening to select patients who would benefit
from EGFR-targeted therapy (Arteaga, 2002).
The orally active EGFR tyrosine kinase inhibitor (EGFR-TKI)
gefitinib (‘Iressa’, ZD1839) is a leading agent in the field of EGFR-
targeted therapy. In two large Phase II trials involving pretreated
patients with advanced NSCLC, gefitinib monotherapy was well
tolerated and demonstrated clinically meaningful antitumour
activity (Fukuoka et al,2 0 0 3 ;K r i set al, 2003). Objective response
rates of 12–18% were observed with gefitinib 250mgday
 1 and over
40% of patients had disease control. In addition, symptom relief was
experienced by approximately 40% of symptomatic patients. Two
Phase III trials of docetaxel as second-line treatment of NSCLC
reported objective response rates of 5.5–6.7%, while in another
Phase III trial that compared second-line docetaxel and pemetrexed,
objective response rates of 9% were observed in both arms (Fossella
et al, 2000; Shepherd et al, 2000; Hanna et al, 2003) An Expanded
Access Programme (EAP) has contributed to the extensive clinical
experience with gefitinib; to date, more than 92000 patients have
been treated with this novel agent worldwide (Forsythe and
Faulkner, 2003), including more than 39000 in the EAP.
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lHere, we report our results with a cohort of patients who
received gefitinib as part of the EAP in Italy. This investigation was
designed to help resolve whether EGFR expression could be used
as a predictive factor for response to EGFR-targeted agents. We
evaluated whether EGFR expression levels could predict as to
which patients would exhibit a response or disease control after
treatment with gefitinib, and whether there was a correlation
between EGFR status and survival.
PATIENTS AND METHODS
Eligibility and treatment
Patients were eligible for inclusion in the EAP if no other standard
treatment options were available to them and if they were ineligible
for clinical trials with gefitinib. Each patient was required to have
adequate haematological, renal and cardiac function, to be aged
X18 years, and to provide written, informed consent. Oral
gefitinib was supplied at a dose of 250mgday
 1 for an indefinite
period or until disease progression or unacceptable toxicity. To be
eligible for the investigation, patients must have a complete record
of clinical parameters and assessment of EGFR expression.
Clinical assessment
Objective tumour response was assessed as complete response (CR),
partial response (PR), stable disease (SD) or disease progression
every 6 weeks according to the International Union Against Cancer/
World Health Organisation criteria (Green and Weiss, 1992).
Disease control was defined as the best tumour response of CR, PR
or SD, confirmed and sustained for X4 weeks. Survival was
assessed from the date that gefitinib treatment commenced to the
date of death, and survival curves were constructed using the
Kaplan–Meier method. The duration of response was calculated (in
patients with CR or PR) as the time from the first observed response
until documented disease progression. The duration of disease
control (in patients with CR, PR or SD) was calculated from the
initiation of treatment until documented disease progression.
Adverse events were graded according to National Cancer Institute
Common Toxicity Criteria version 2.0.
Detection of EGFR expression
Membrane EGFR immunoreactivity in paraffin-embedded tissues
was analysed by immunohistochemistry using the monoclonal
antibody EGFrAb-10 (clone 111.6) and the DAKO EnVisiont
visualisation system. Tissue samples were classified according to the
level of EGFR expression. The staining intensity of immuno-
reactive cells was evaluated to be negative to faint (0/1þ)o r
medium to strong (2þ/3þ), as shown in Figure 1. In addition, the
percentage of neoplastic cells showing membranous immuno-
reactivity was evaluated semiquantitatively. Patient samples with
0–19% immunoreactive cells were classified as negative/low
expressors, and those with X20% immunoreactive cells were
classified as high expressors. Both assessments of EGFR expression
were scored blindly by two independent observers, who reached
concordance for scoring in 480% of the cases. The discordant cases
were scored after a consensus meeting at a double-head microscope.
A w
2 test was used to determine if EGFR staining intensity correlated
with baseline patient characteristics or response.
RESULTS
Patients
From January 2001 to May 2003, 147 patients with stage I–IV
NSCLC were enrolled in the EAP at the Istituto Clinico Humanitas.
In total, 50 patients were evaluable for assessment, with a complete
record of clinical data and measurement of their EGFR status. This
subset of patients is representative of the total patient population
treated with gefitinib in our centre; baseline patient demographics
are presented in Table 1. Most patients had stage III/IV disease
(90%) and had previously received at least one prior chemotherapy
regimen (86%).
Clinical outcome
Responses were only observed in patients with adenocarcinoma,
with an overall response rate of 10% (one CR and four PR). An
additional 20 patients achieved SD, amounting to a disease control
rate of 50%. The median (range) durations of response and disease
control were 4 (2–12) months and 6 (2–17) months, respectively.
EGFR strong staining intensity: 3+
EGFR medium staining intensity: 2+
EGFR faint staining intensity: 1+
Figure 1 EGFR staining intensity.
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lThe median (range) survival was 4 (1–17) months (Figure 2) for all
evaluable patients and 9 (2–17) months in patients with disease
control. The 1-year survival rate was 18%.
All patients (n¼50) were evaluable for toxicity. Nonhaemato-
logical toxicity was mild. Grade 1/2 and grade 3 skin rash was
observed in 30 (60%) and four (2%) patients, respectively. In total,
21 patients (42%) had grade 1 diarrhoea. No haematological
toxicity was observed.
EGFR expression and clinical outcome
Correlation analysis between patient characteristics and EGFR
status showed that squamous-cell carcinomas were statistically
significantly more likely to express EGFR than adenocarcinoma or
other histological subtypes (P¼0.009) (Table 2). There was no
statistically significant difference in EGFR expression related to
age, sex or PS.
There was no significant correlation between response and
EGFR staining intensity (P¼0.108), or between disease control
and EGFR staining intensity (P¼0.39) (Table 3). Within the subset
of patients with adenocarcinoma (n¼29), there was no significant
correlation between staining intensity and disease control, but
there was a significant correlation between response and an EGFR
status of 2þ/3þ (P¼0.009) (Table 4).
Evaluation of survival rates for all evaluable patients (n¼50)
showed that patients with an EGFR status of 0/1þ survived
statistically significantly longer than patients with an EGFR status
of 2þ/3þ (P¼0.03) (Figure 3), which is consistent with earlier
observations that high EGFR correlates with poor prognosis in
NSCLC. Analysis of the patients who achieved disease control
(n¼25) revealed similar results; those with an EGFR status of 0/
1þ had a longer survival than patients with an EGFR status of
2þ/3þ, but this difference was not statistically significant.
DISCUSSION
For this group of 50 patients with NSCLC, who received gefitinib
on a compassionate-use basis, there were promising objective
tumour response and disease control rates of 10 and 50%,
respectively. These results are consistent with those of two major
Phase II monotherapy trials (IDEAL (‘Iressa’ Dose Evaluation in
Advanced Lung cancer) 1 and 2) of gefitinib in patients with
advanced NSCLC, which reported objective response rates of 11.8–
18.4% and disease control rates of 42.2–54.4% (Fukuoka et al,
2003; Kris et al, 2003). Our experience in this investigation
Table 1 Baseline patient demographics
Characteristic
Evaluable
patients
(n¼50)
Total patient
population
(n¼147)
Male:female, n (%) 38:12 (76:24) 110:37 (75:25)
Mean age (range), years 62 (36–80) 62 (28–82)
Performance status, n (%)
0–1 37 (74) 117 (80)
2 13 (26) 30 (20)
Stage at trial entry, n (%)
I–II 5 (10) 16 (11)
III–IV 45 (90) 131 (89)
Histological subtype, n (%)
Adenocarcinoma 29 (58) 74 (50)
Squamous-cell carcinoma 9 (18) 28 (19)
Poorly differentiated carcinoma 10 (20) 27 (18)
Carcinoma NOS 2 (4) 16 (11)
Other 0 2 (1)
Previous chemotherapy, n (%)
None 7 (14) 14 (10)
1st line 28 (56) 76 (52)
X2nd line 15 (30) 57 (38)
Previous radiotherapy, n (%)
Yes 29 (58) 75 (51)
No 21 (42) 72 (49)
EGFR status – staining intensity, n (%)
0/1+ 27 (54) n/a
2+/3+ 23 (46)
EGFR status – immunoreactive cells, n (%)
NLE 29 (58) n/a
HE 21 (42)
HE¼high expressor; NLE¼negative/low expressor; NOS¼not otherwise specified;
n/a¼not applicable.
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Figure 2 Kaplan–Meier plot showing overall survival in all evaluable
patients (n¼50).
Table 2 EGFR status according to patient characteristics
Staining intensity
No. of patients
(n¼50) 0/1+ n (%) 2+/3+ n (%)
Histology
Adenocarcinoma 29 20 (69) 9 (31)
Squamous-cell carcinoma 9 1 (11) 8 (89)
Other 12 6 (50) 6 (50)
P¼0.009
a
Age
o60 years 21 7 (33) 14 (67)
X60 years 29 16 (55) 13 (45)
P¼0.12
a
Sex
Female 12 4 (33) 8 (67)
Male 38 19 (50) 19 (50)
P¼0.31
a
Performance status
0–1 37 16 (59) 21 (41)
X2 13 7 (54) 6 (46)
P¼0.57
a
aw
2 test.
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patients with NSCLC who have no alternative treatment options.
In this series of patients treated with gefitinib, strong EGFR
staining (2þ/3þ) correlated with shorter survival time, indicat-
ing that high EGFR expression is associated with poor prognosis.
These results concur with other studies that have reported that
EGFR expression assessed by immunohistochemistry is associated
with shorter survival in patients with NSCLC (Volm et al, 1998;
Ohsaki et al, 2000). However, a retrospective analysis of over 200
studies in different tumour types concluded that EGFR expression
was a weak prognostic factor for NSCLC (Nicholson et al, 2001).
The lack of clear consensus on this issue is partly due to the
variation in EGFR detection methods used (Nicholson et al, 2001;
Arteaga, 2002; Ciardiello and Tortora, 2003). Immunohistochem-
istry is arguably the most appropriate method, as this detects
EGFR protein expression. However, there is currently no
standardised assay in use, and differences in techniques and
scoring systems prevent direct comparison between study results.
The development of a standardised assay is paramount to
resolving this issue.
Table 3 EGFR status by response and disease control
Staining intensity Immunoreactive cells
No. of patients (n¼50) 0/1+ n (%) 2+/3+ n (%) NLE n (%) HE n (%)
Response
Yes 5 1 (20) 4 (80) 2 (40) 3 (60)
No 45 26 (58) 19 (42) 27 (60) 18 (40)
P¼0.108
a P¼0.39
a
Disease control
Yes 25 15 (60) 10 (40) 17 (68) 8 (32)
No 25 12 (48) 13 (52) 12 (48) 13 (52)
P¼0.39
a P¼0.15
a
aw
2 test. Response¼CR+PR; Disease control¼CR+PR+SD.
Table 4 EGFR status and response in patients with adenocarcinoma
Staining intensity Immunoreactive cells
No. of patients (n¼29) 0/1+ n (%) 2+/3+ n (%) NLE n (%) HE n (%)
Response
Yes 5 1 (20) 4 (80) 2 (40) 3 (60)
No 24 19 (79) 5 (21) 19 (79) 5 (21)
P¼0.009
a P¼0.07
a
Disease control
Yes 17 12 (71) 5 (29) 13 (76) 4 (24)
No 12 8 (67) 4 (33) 8 (67) 4 (33)
P¼0.82
a P¼0.56
a
aw
2 test. Response¼CR+PR; Disease control¼CR+PR+SD.
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Figure 3 Kaplan–Meier plots showing survival according to EGFR staining intensity (n¼50).
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lOur results demonstrated no significant correlation between
EGFR expression and either objective response or disease control
resulting from gefitinib treatment. This is consistent with a recent
study that assessed the correlation of EGFR membrane staining
with the probability of objective response or symptom improve-
ment resulting from gefitinib treatment in IDEAL 1 and 2. The
analysis found no consistent association between EGFR expression
and clinical outcome (Bailey et al, 2003). Objective responses or
symptom relief were observed in some patients with no detectable
EGFR staining, but not in other patients who had intense EGFR
staining. These data suggest that tumour EGFR membrane staining
is not clinically relevant for predicting response to gefitinib.
Furthermore, although patients with adenocarcinoma in this
investigation were less likely to express EGFR than other
histological subtypes, all objective responses were observed in
patients with adenocarcinoma. Within this group there was a
correlation between EGFR expression and objective response, but
not disease control. High EGFR expression is more common in
squamous-cell carcinomas than adenocarcinomas (Franklin et al,
2002), yet adenocarcinoma was identified as a potential prognostic
factor in IDEAL 1 (Fukuoka et al, 2003). A proposed explanation
has highlighted the coexpression of EGFR and high levels of HER2
in adenocarcinoma (Johnson and Arteaga, 2003). The increased
potential for the formation of EGFR-HER2 heterodimers, which
induce a stronger and more sustained signal than EGFR
homodimers (Yarden and Sliwkowski, 2001), could result in
greater reliance on this signalling network in adenocarcinoma and
consequently greater sensitivity to inhibition of EGFR signalling.
As well as interactions with HER2 and other EGFR receptor
family members, a number of other factors influence EGFR
signalling in cancer cells, such as receptor mutations and increased
expression of ligands (Arteaga, 2002; Ciardiello and Tortora, 2003).
In addition, the EGFR mediates a complex network of downstream
pathways that are also influenced by other signalling systems.
Thus, focusing on EGFR expression levels alone might give an
oversimplified view when trying to evaluate the relationship
between the EGFR and response to an EGFR-targeted agent.
In conclusion, this investigation has shown that analysis of
EGFR expression is not useful for the prediction of clinical
outcome with gefitinib treatment in patients with advanced
NSCLC. Future research should address the requirement for a
standardised quantitative assay for EGFR, as well as developing
assays that take further consideration of the effect of different
histological subtypes on the biology of the EGFR signalling
network.
‘Iressa’ is a trademark of the AstraZeneca group of companies.
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